OKYO Pharma Announces Chairman and Founder Acquires Shares

Summary by AI BETAClose X

OKYO Pharma announced that Panetta Partners Limited, an entity with beneficial interest to the Executive Chairman, acquired 210,000 of the company’s ordinary shares on NASDAQ. This acquisition increases the Executive Chairman's total holding to 10,382,677 shares. The company is focused on developing urcosimod for neuropathic corneal pain, an ocular condition lacking FDA-approved therapies. Urcosimod, a lipid conjugated chemerin peptide agonist, has shown promise in treating ocular diseases and recently completed a Phase 2 trial for neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings